347 related articles for article (PubMed ID: 28066188)
1. Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease.
Grosch J; Winkler J; Kohl Z
Front Cell Neurosci; 2016; 10():293. PubMed ID: 28066188
[TBL] [Abstract][Full Text] [Related]
2. Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease.
Kohl Z; Ben Abdallah N; Vogelgsang J; Tischer L; Deusser J; Amato D; Anderson S; Müller CP; Riess O; Masliah E; Nuber S; Winkler J
Neurobiol Dis; 2016 Jan; 85():206-217. PubMed ID: 26523794
[TBL] [Abstract][Full Text] [Related]
3. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
4. Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson's Disease.
Bellucci A; Bubacco L; Longhena F; Parrella E; Faustini G; Porrini V; Bono F; Missale C; Pizzi M
Front Aging Neurosci; 2020; 12():68. PubMed ID: 32265684
[TBL] [Abstract][Full Text] [Related]
5. Review: Parkinson's disease: from synaptic loss to connectome dysfunction.
Bellucci A; Mercuri NB; Venneri A; Faustini G; Longhena F; Pizzi M; Missale C; Spano P
Neuropathol Appl Neurobiol; 2016 Feb; 42(1):77-94. PubMed ID: 26613567
[TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanisms Underlying Synaptic and Axon Degeneration in Parkinson's Disease.
Gcwensa NZ; Russell DL; Cowell RM; Volpicelli-Daley LA
Front Cell Neurosci; 2021; 15():626128. PubMed ID: 33737866
[TBL] [Abstract][Full Text] [Related]
7. Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease.
O'Keeffe GW; Sullivan AM
Parkinsonism Relat Disord; 2018 Nov; 56():9-15. PubMed ID: 29934196
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
9. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?
Jellinger KA
J Neural Transm Suppl; 1999; 56():1-29. PubMed ID: 10370901
[TBL] [Abstract][Full Text] [Related]
10. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
[TBL] [Abstract][Full Text] [Related]
11. The Role of α-Synuclein in the Regulation of Serotonin System: Physiological and Pathological Features.
Miquel-Rio L; Sarriés-Serrano U; Pavia-Collado R; Meana JJ; Bortolozzi A
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831077
[TBL] [Abstract][Full Text] [Related]
12. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
13. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
15. Hyper-serotonergic state determines onset and progression of idiopathic Parkinson's disease.
da Cruz Moreira-Junior E
Med Hypotheses; 2019 Dec; 133():109399. PubMed ID: 31542611
[TBL] [Abstract][Full Text] [Related]
16. Lateral habenula as a link between dopaminergic and serotonergic systems contributes to depressive symptoms in Parkinson's disease.
Luo XF; Zhang BL; Li JC; Yang YY; Sun YF; Zhao H
Brain Res Bull; 2015 Jan; 110():40-6. PubMed ID: 25499570
[TBL] [Abstract][Full Text] [Related]
17. Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia.
Vegas-Suarez S; Paredes-Rodriguez E; Aristieta A; Lafuente JV; Miguelez C; Ugedo L
Int Rev Neurobiol; 2019; 146():259-279. PubMed ID: 31349930
[TBL] [Abstract][Full Text] [Related]
18. Dopamine, Alpha-Synuclein, and Mitochondrial Dysfunctions in Parkinsonian Eyes.
Indrieri A; Pizzarelli R; Franco B; De Leonibus E
Front Neurosci; 2020; 14():567129. PubMed ID: 33192254
[TBL] [Abstract][Full Text] [Related]
19. The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease.
Goulding SR; Sullivan AM; O'Keeffe GW; Collins LM
Neural Regen Res; 2020 Aug; 15(8):1432-1436. PubMed ID: 31997802
[TBL] [Abstract][Full Text] [Related]
20. Layer-specific axonal degeneration of serotonergic fibers in the prefrontal cortex of aged A53T α-synuclein-expressing mice.
Wihan J; Grosch J; Kalinichenko LS; Müller CP; Winkler J; Kohl Z
Neurobiol Aging; 2019 Aug; 80():29-37. PubMed ID: 31077958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
